Notice of Refund | Dec 1, 2017 | PAPER | BOARD |
Petitioner's Request for Refund of Post-Institution Fee | Nov 29, 2017 | PAPER | PETITIONER |
Decision Denying Institution of Inter Partes Review | Sep 7, 2017 | PAPER | BOARD |
Daugherty 2006 | Jun 11, 2017 | EXHIBIT | PATENT OWNER |
Humphreys 2015 | Jun 11, 2017 | EXHIBIT | PATENT OWNER |
Wang 2007 | Jun 11, 2017 | EXHIBIT | PATENT OWNER |
ZEVALIN Label | Jun 11, 2017 | EXHIBIT | PATENT OWNER |
Patent Owner's Updated Power of Attorney | Jun 11, 2017 | PAPER | PATENT OWNER |
Patent Owner's Updated Mandatory Notices | Jun 11, 2017 | PAPER | PATENT OWNER |
Patent Owner's Preliminary Response | Jun 11, 2017 | PAPER | PATENT OWNER |
Rouet 2014 | Jun 11, 2017 | EXHIBIT | PATENT OWNER |
Shire 2015 | Jun 11, 2017 | EXHIBIT | PATENT OWNER |
REPLACEMENT PETITION FOR INTER PARTES REVIEW OF UNITED STATES PATENT NO. 9,085,619 PURSUANT TO 35 U.S.C. ¿¿¿¿ 311¿¿¿319 AND 37 C.F.R. ¿¿ 42 | Apr 10, 2017 | PAPER | PETITIONER |
Replacement Exhibit 1102 - Radtke Declaration | Apr 10, 2017 | EXHIBIT | PETITIONER |
Replacement Exhibit 1105 - Humira in PDR 2004 | Apr 10, 2017 | EXHIBIT | PETITIONER |
Replacement Exhibit 1108 - Gamimune in PDR 2002 | Apr 10, 2017 | EXHIBIT | PETITIONER |
Order Conduct of the Proceeding | Apr 7, 2017 | PAPER | BOARD |
Petitioner's Updated Mandatory Notices | Mar 23, 2017 | PAPER | PETITIONER |
Patent Owner's Second Updated Mandatory Notices | Mar 17, 2017 | PAPER | PATENT OWNER |
Patent Owner's Updated Mandatory Notices | Feb 27, 2017 | PAPER | PATENT OWNER |
Notice of Accord Filing Date | Feb 24, 2017 | PAPER | BOARD |
Patent Owner's Power of Attorney | Feb 21, 2017 | PAPER | PATENT OWNER |
Patent Owner's Mandatory Notices | Feb 21, 2017 | PAPER | PATENT OWNER |
U.S. Patent No. 9,085,619 | Jan 31, 2017 | EXHIBIT | PETITIONER |
U.S. Pub. No. 2016/0319011, Gokarn et al. | Jan 31, 2017 | EXHIBIT | PETITIONER |
HUMIRA¿¿ Label (Jan. 2003) | Jan 31, 2017 | EXHIBIT | PETITIONER |
HUMIRA¿¿ Label (Jan. 2008) | Jan 31, 2017 | EXHIBIT | PETITIONER |
Adalimumab Product Approval Information | Jan 31, 2017 | EXHIBIT | PETITIONER |
PETITION FOR INTER PARTES REVIEW OF UNITED STATES PATENT NO. 9,085,619 PURSUANT TO 35 U.S.C. ¿¿¿¿ 311¿¿¿319 AND 37 C.F.R. ¿¿ 42 | Jan 31, 2017 | PAPER | PETITIONER |
Declaration of Klaus-Peter Radtke, Ph.D. | Jan 31, 2017 | EXHIBIT | PETITIONER |
U.S. App. 60/690,582 to Gokarn et al. | Jan 31, 2017 | EXHIBIT | PETITIONER |
GAMIMUNE¿¿ Label (Oct. 2005) | Jan 31, 2017 | EXHIBIT | PETITIONER |
SYNAGIS¿¿ Label (July 2004) | Jan 31, 2017 | EXHIBIT | PETITIONER |
AVASTINTM Label (Feb. 2004) | Jan 31, 2017 | EXHIBIT | PETITIONER |
TYSABRI¿¿ Label (Nov. 2004) | Jan 31, 2017 | EXHIBIT | PETITIONER |
AbbVie Biotechnology Ltd., ¿¿¿Patent Owner¿¿¿s Preliminary Response,¿¿¿ | Jan 31, 2017 | EXHIBIT | PETITIONER |
AbbVie Biotechnology Ltd., ¿¿¿Annex A ¿¿¿ The Humira¿¿ Story,¿¿¿ | Jan 31, 2017 | EXHIBIT | PETITIONER |
Christensen, ¿¿¿Proteins as buffers,¿¿¿ | Jan 31, 2017 | EXHIBIT | PETITIONER |
Van Slyke, ¿¿¿On the Measurement of Buffer Values and on the..." | Jan 31, 2017 | EXHIBIT | PETITIONER |
Fransson & Espander-Jansson, ¿¿¿Local Tolerance of Subcutaneous Injections,¿¿¿ | Jan 31, 2017 | EXHIBIT | PETITIONER |
Nozaki & Tanford, ¿¿¿Examination of Titration Behavior,¿¿¿ | Jan 31, 2017 | EXHIBIT | PETITIONER |
Olthuis et al., ¿¿¿Characterization of Proteins by Means of their Buffer Capacity..." | Jan 31, 2017 | EXHIBIT | PETITIONER |
Parslow, ¿¿¿Immunoglobulins & Immunoglobulin Genes,¿¿¿ | Jan 31, 2017 | EXHIBIT | PETITIONER |
Gokarn et al., ¿¿¿Excipients for Protein Drugs,¿¿¿ | Jan 31, 2017 | EXHIBIT | PETITIONER |
Physicians¿¿¿ Desk Reference, pp. 558-59, 914-31, 805-07, 2026-28, 2295-97, 2524-25 (56th ed. 2002) | Jan 31, 2017 | EXHIBIT | PETITIONER |
U.S. Prosecution History of App. No. 14/506,576 | Jan 31, 2017 | EXHIBIT | PETITIONER |
U.S. Prosecution History of App. No. 13/774,735 (Part 1) | Jan 31, 2017 | EXHIBIT | PETITIONER |
U.S. Prosecution History of App. No. 12/325,049 (Part 3) | Jan 31, 2017 | EXHIBIT | PETITIONER |
U.S. Prosecution History of App. No. 12/325,049 (Part 5) | Jan 31, 2017 | EXHIBIT | PETITIONER |
Stoner et al., ¿¿¿Protein¿¿¿Solute Interactions Affect the Outcome..." | Jan 31, 2017 | EXHIBIT | PETITIONER |
U.S. Prosecution History of App. No. 13/774,735 (Part 2) | Jan 31, 2017 | EXHIBIT | PETITIONER |
U.S. Prosecution History of App. No. 12/325,049 (Part 1) | Jan 31, 2017 | EXHIBIT | PETITIONER |
U.S. Prosecution History of App. No. 12/325,049 (Part 2) | Jan 31, 2017 | EXHIBIT | PETITIONER |
U.S. Prosecution History of App. No. 12/325,049 (Part 4) | Jan 31, 2017 | EXHIBIT | PETITIONER |
U.S. Prosecution History of App. No. 12/325,049 (Part 6) | Jan 31, 2017 | EXHIBIT | PETITIONER |
U.S. Prosecution History of App. No. 61/004,992 | Jan 31, 2017 | EXHIBIT | PETITIONER |
¿¿¿Fraunhofer Substantive Motion 3,¿¿¿ in Fraunhofer v. Gokarn, Patent Interference No. 106,057 | Jan 31, 2017 | EXHIBIT | PETITIONER |
U.S. Pub. No. 2004/0033535, Boyle et al. | Jan 31, 2017 | EXHIBIT | PETITIONER |
Gebhart, ¿¿¿Biotech Company Preparing Several Drugs for Takeoff,¿¿¿ | Jan 31, 2017 | EXHIBIT | PETITIONER |
Schwartz, ¿¿¿Diafiltration for Desalting of Buffer Exchange,¿¿¿ BioProcess Int¿¿¿l | Jan 31, 2017 | EXHIBIT | PETITIONER |
Carnahan et al., ¿¿¿Epratuzumab, a Humanized Monoclonal Antibody Targeting CD22: Characterization of In Vitro Properties,¿¿¿ | Jan 31, 2017 | EXHIBIT | PETITIONER |
WO 2006/138181 | Jan 31, 2017 | EXHIBIT | PETITIONER |
WO 1997/029131 | Jan 31, 2017 | EXHIBIT | PETITIONER |
HUMIRA¿¿ Label (Nov. 2015) | Jan 31, 2017 | EXHIBIT | PETITIONER |
HUMIRA¿¿ Label (Oct. 2016) | Jan 31, 2017 | EXHIBIT | PETITIONER |
Vivaglobin¿¿ Label (Jan. 2006) | Jan 31, 2017 | EXHIBIT | PETITIONER |
GAMMAGARD LIQUID Label (April 2005) | Jan 31, 2017 | EXHIBIT | PETITIONER |
VectibixTM Label (Sept. 2006) | Jan 31, 2017 | EXHIBIT | PETITIONER |
Butler & Hamilton, ¿¿¿Quantitation of Specific Antibodies: Methods of Express, Standards, Solid-Phase Considerations, and Specific Applications,¿¿¿ | Jan 31, 2017 | EXHIBIT | PETITIONER |
Jefferis et al., ¿¿¿Recognition Sites on Human IgG for Fc¿¿ Receptors: The Role of Glycosylation,¿¿¿ | Jan 31, 2017 | EXHIBIT | PETITIONER |
Cleland & Langer, ¿¿¿Formulation and Delivery of Proteins and Peptides: Design and Development Strategies,¿¿¿ | Jan 31, 2017 | EXHIBIT | PETITIONER |
Press Release | Jan 31, 2017 | EXHIBIT | PETITIONER |
U.S. Pub. No. 2013/0273066 | Jan 31, 2017 | EXHIBIT | PETITIONER |
U.S. Pub. No. 2012/0028877 | Jan 31, 2017 | EXHIBIT | PETITIONER |
U.S. Pub. No. 2008/0311078 | Jan 31, 2017 | EXHIBIT | PETITIONER |
U.S. Patent No. 6,090,382 | Jan 31, 2017 | EXHIBIT | PETITIONER |
CNJ-016 (Vaccinia Immune Globulin Intravenous) Label (Jan. 2010) | Jan 31, 2017 | EXHIBIT | PETITIONER |
OCTAGAM¿¿ Label (Mar. 2004) | Jan 31, 2017 | EXHIBIT | PETITIONER |
Flebogamma¿¿ Label (Jan. 2004) | Jan 31, 2017 | EXHIBIT | PETITIONER |
GAMUNEX¿¿ Label (Nov. 2005) | Jan 31, 2017 | EXHIBIT | PETITIONER |
Privigen¿¿ Label (Oct. 2016) | Jan 31, 2017 | EXHIBIT | PETITIONER |
HepaGam BTM Summary Basis for Approval (Jan. 2006) | Jan 31, 2017 | EXHIBIT | PETITIONER |
McDonnell, ¿¿¿Production of Antibodies in Hybridoma and Non-hybridoma Cell Lines,¿¿¿ | Jan 31, 2017 | EXHIBIT | PETITIONER |
Akers et al., ¿¿¿Formulation Development of Protein Dosage Forms,¿¿¿ | Jan 31, 2017 | EXHIBIT | PETITIONER |
Hanna, The IGIV-C Study Group, ¿¿¿Tolerability of a New Intravenous Immunoglobulin Preparation (IGIV) in Pediatric and Adult Patients,¿¿¿ | Jan 31, 2017 | EXHIBIT | PETITIONER |
Frenken et al., ¿¿¿Identification of the Component Part in an Epoetin Alfa Preparation that Causes Pain after Subcutaneous Injection,¿¿¿ | Jan 31, 2017 | EXHIBIT | PETITIONER |
Gelfand, ¿¿¿Differences Between IGIV Products: Impact on Clinical Outcome,¿¿¿ | Jan 31, 2017 | EXHIBIT | PETITIONER |
Handbook of Pharmaceutical Excipients | Jan 31, 2017 | EXHIBIT | PETITIONER |
U.S. Pub. No. 2003/0138417 | Jan 31, 2017 | EXHIBIT | PETITIONER |
Laursen et al., “Pain Perception after Subcutaneous Injections of Media Containing Different Buffers,” | Jan 31, 2017 | EXHIBIT | PETITIONER |
Campath¿¿ Label (Aug. 2006) | Jan 31, 2017 | EXHIBIT | PETITIONER |
PETITIONER'S POWER OF ATTORNEY PURSUANT TO 37 CFR 42.lO(b) | Jan 31, 2017 | PAPER | PETITIONER |